

Category

Best Startup

General Information**Company Name ***

CUTISS AG

Turnover and/or Funding

0 TURNOVER, 95M\$ RAISED TO DATE (JUNE 2025)

words remaining :

492

Sub-Category *

Biotechnology

Background

Corporate history (creation, key milestones, main funding,...)Information on Condition / Disease and need for solution / product (prevalence, existing treatments / solutions)
(please be as specific as possible in your description; limit 500 words)

Founded in Zurich in March 2017, CUTISS AG emerged as a spin-off from the University of Zurich to industrialise denovoSkin™, a revolutionary autologous skin tissue therapy for skin surgery. The company has secured above \$ 95 million and is currently running Phase III program in EU under Orphan Drug Status for Burns, and automation industrialization to scale production. The US program will start soon.

Large and deep wounds e.g. burns, trauma, plastic and reconstructive remain a major global health issue. The WHO estimates about 11 million people require clinical care for burns and in EU and US every year more than 1 million people undergo reconstructive skin surgery.

Standard of care for skin surgery relies on autografting (the harvesting of healthy skin sheets and their grafting on open wounds), facing two major issues: donor site shortage and debilitating, disfiguring scarring, leading to life-long poor quality of life. More than 100 products are on the market to support autografting but inefficiency rules.

denovoSkin™ is uniquely designed to replace autografting. From a stamp-sized biopsy, a large quantity of skin tissue is bio-engineered within 3 weeks, on demand. The product has been tested on over 75 patients, in 4 clinical trials (as well as compassionate patients with life-threatening burns), showing long term safety and efficacy vs autografting in a variety of indications and age groups, incl. neonates: denovoSkin™ can significantly spare donor site and drastically improve scar quality.

The company has a proprietary automated platform to create skin tissue literally anywhere and this platform can be expanded beyond skin in e.g. muscle, gums, corneas ect. The industrialization of the platform is ongoing with a world leading partner, TECAN.

The company is also proposing an add on therapy to restore skin color on demand, for a great cosmetic and sun-exposing patient experience.

Today, CUTISS is a global leader in skin tissue therapy, very close to commercialization. The future leads us to skin organ. How do we get there? CUTISS is doing space research to accelerate discoveries (first SpaceX launch done) and add knowledge to skin regenerative processes incl. those of critical appendages e.g. hair and glands.

words remaining :

148

History of the development of the solution/product (Intellectual Property, preclinical and clinical datas, development collaborations) *

(please be as specific as possible in your description; 500 words)

The product development was initiated in academia by a group of surgeons and scientists. The company has 9 patents (3 granted) and trade secret of the bioprocess. The pre-clinical package includes characterization work in vitro, and in vivo on mice, rats and pigs. In 2014 the first patients were granted in a phase 1 study. The results led to company creation, and controlled randomized phase 2 studies in burns and reconstructive, and now to phase 3. Data has been generated in EU, one patient has been treated at MGH in Boston in 2024. 2 automated modules have been invented, prototyped, tested and now further industrialized to produce skin at scale. A CE marked medical device serves as add on for color restoration.

words remaining :

378

Why this drug or device is innovative, the broad implications for future research, and/or how it will improve the human condition *

Today, people that need or want skin surgery, have one option: autografting. This method was first described in 1500 BC by the Egyptians. It is about time we bring innovation to the field. Great advancements have been made in tissue engineering and skin is our largest organ. It is out, it is us. It gets injured a lot and it must look good:) (not the same as a liver:). We aim at providing patients their skin back, their life back. People that live with scars, do not live as they deserve.

words remaining :

409

Please provide appropriate references (PubMed, Abstract, Website) *

www.cutiss.swiss

<https://cutiss.swiss/clinical-problem-scars/> (see publications)

Our first US case at MGH on Boston Globe: a complex reconstruction on a 90% burn toddler survivor
<https://cutiss.swiss/the-boston-globe-reports-on-first-u-s-patient-treated-with-denovoskin/>

A patient story on BBC: a 95% burn child

<https://www.youtube.com/watch?v=KB87eLYja6o>

A reportage on Bloomberg: CUTISS and its unique tech

<https://www.youtube.com/watch?v=ItMoJMD-qXs&t=584s>

Two recent podcasts of mine: My vision and mission to revolutionize regenerative medicine

<https://www.biotechtv.com/post/cutiss-may-1-2025>

<https://flot.bio/episode/daniela-marino-cutiss-skin-tissue-therapeutics/>

*Kindly clearly label your files with company name and asset name.

Attached Files:

- [CUTISS_5 PITCH_denovoskin Q2 2025.pdf](#)